UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 230

Sortiert nach

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Journal of clinical oncology, 2013-01, Vol.31 (1), p.88-94

2013

Volltextzugriff (PDF)

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2014-03, Vol.370 (11), p.997-1007

2014

Volltextzugriff (PDF)

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Blood, 2015-12, Vol.126 (26), p.2798-2804

2015

Volltextzugriff (PDF)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Haematologica (Roma), 2022-11, Vol.107 (11), p.2630

2022

Volltextzugriff (PDF)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Haematologica (Roma), 2022-06, Vol.107 (6), p.1335

2022

Volltextzugriff (PDF)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Frontiers in oncology, 2021-11, Vol.11, p.720704-720704

2021

Volltextzugriff (PDF)

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood, 2023-04, Vol.141 (16), p.1971-1981

2023

Volltextzugriff (PDF)

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Blood, 2016-01, Vol.127 (1), p.79-86

2016

Volltextzugriff (PDF)

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

Proceedings of the National Academy of Sciences - PNAS, 2010-07, Vol.107 (29), p.12747-12754

2010

Volltextzugriff (PDF)

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Haematologica (Roma), 2022-04, Vol.107 (4), p.984

2022

Volltextzugriff (PDF)

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Haematologica (Roma), 2022-01, Vol.107 (1), p.134

2022

Volltextzugriff (PDF)

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Haematologica (Roma), 2016-07, Vol.101 (7), p.e295

2016

Volltextzugriff (PDF)

Targeting CD20: teaching an old dog new tricks

Hematology, 2019-12, Vol.2019 (1), p.273-278

Sharman, Jeff P

2019

Volltextzugriff (PDF)

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2022-01, Vol.386 (4), p.351-363

2022

Volltextzugriff (PDF)

ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma

Blood reviews, 2022-11, Vol.56, p.100967-100967, Article 100967

2022

Volltextzugriff (PDF)

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical cancer research, 2020-08, Vol.26 (15), p.3918-3927

2020

Volltextzugriff (PDF)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

EJHaem, 2023-02, Vol.4 (1), p.135-144

2023

Volltextzugriff (PDF)

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2014-03, Vol.370 (11), p.997-1007

2014

Volltextzugriff (PDF)

Obinutuzumab Can Be Administered as a 90‐minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

HemaSphere, 2023-04, Vol.7 (4), p.e860-n/a

2023

Volltextzugriff (PDF)

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2013-07, Vol.369 (1), p.32-42

2013

Volltextzugriff (PDF)

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

The lancet oncology, 2019-07, Vol.20 (7), p.998-1010

2019

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(205)

Publikationsform

Artikel
(229)
Reviews
(1)

Sprache

Englisch
(230)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(96)
Life Sciences & Biomedicine
(93)
Humans
(79)
Male
(53)
Hematology
(45)
Female
(44)
Middle Aged
(39)
Adult
(38)
Aged
(36)
Oncology
(34)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(31)
Aged, 80 And Over
(24)
Chronic Lymphocytic Leukemia
(19)
Biological And Medical Sciences
(17)
Medical Sciences
(14)
Treatment Outcome
(14)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(13)
Leukemia
(12)
Prognosis
(12)
Antineoplastic Agents - Therapeutic Use
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Targeting CD20: teaching an old dog new tricks

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Obinutuzumab Can Be Administered as a 90‐minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Suchergebnisse filtern